Multimeric Ribonucleoprotein Vaccine Platform Adjuvant-Free Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine technologies face challenges in developing new antigen production and delivery strategies that avoid the use of chemical adjuvants due to safety concerns, and there is a need for effective delivery systems that can elicit both humoral and cell-mediated immune responses without the need for adjuvants.
Innovation Solution
A subunit vaccine platform based on multimeric ribonucleoproteins (RNPs) is developed using recombinant yeast, where the nucleoprotein of a non-segmented negative-strand RNA virus is fused with heterologous polypeptides, allowing for the spontaneous auto-assembly of RNPs that can deliver epitopes and induce an immune response without the use of adjuvants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemical adjuvants are used to enhance immune response, then immune response strength is improved, but safety is worsened due to safety concerns
Solution Approach 1:
The patent extracts and removes chemical adjuvants from the vaccine system, relying instead on the inherent immunogenic properties of yeast-based delivery systems and multimeric RNP structures to elicit immune responses without harmful chemical additives
Solution Approach 2:
The yeast-based delivery system and multimeric RNP structures provide self-adjuvanting properties, where the vaccine platform itself generates the necessary immune stimulation without requiring external chemical adjuvants, making the system self-sufficient and safer
2Reliability
If new antigen production and delivery strategies are developed, then vaccine effectiveness is improved, but complexity of the system increases
Solution Approach 1:
The yeast-based delivery system serves multiple functions simultaneously: it acts as an antigen production platform, a delivery vehicle, and an inherent adjuvant system, reducing the need for separate complex components while maintaining vaccine effectiveness
Solution Approach 2:
The patent employs composite structures combining yeast cells with multimeric ribonucleoprotein complexes, creating a integrated platform that achieves enhanced vaccine effectiveness through the synergistic properties of the composite system rather than through increased complexity of individual components
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNP-based vaccine platform effectively elicits protective immune responses by delivering heterologous polypeptides, demonstrating its potential as a safe and adjuvant-free method for vaccine development, as shown in a malaria animal model, where it induced significant parasitemia delay and antibody production.
Implementation Method 1
the spontaneous auto-assembly of RNPs that can deliver epitopes
Data Source
Figure 1~2
Figure 3A~3B
Figure 4A~4F
AI summary
The present invention relates to a subunit vaccine platform based on multimeric ribonucleoproteins (RNPs) comprising nucleoproteins of a non- segmented negative-strand ribonucleic acid (RNA) virus as carriers of heterologous polypeptides. The present invention also relates to multimeric RNPs resulting from the assembly of at least 200 fusion proteins with a cellular RNA, or to recombinant yeasts or yeast lysates expressing these multimeric RNPs. It also concerns a process for the preparation of these multimeric RNPs or recombinant yeasts or yeast lysates. In particular, the present invention relates to their use as active ingredient for the in vitro production of an immunogenic composition or in eliciting a protective prophylactic or a therapeutic immune response against said heterologous polypeptide in a host in need thereof. Recombinant yeasts or yeast lysates of the invention can also be used as expression and vector systems for delivery to a host.